| BYND 1.17 0.86% | CTNT 0.0388 -29.20% | FCHL 0.2876 27.82% | FFAI 0.4721 64.67% | LOBO 0.725 26.62% | ASBP 0.1949 -25.58% | RPGL 0.6384 41.90% | TZA 5.075 1.60% | XRTX 2.725 21.11% | LOCL 2.7304 45.23% | EDBL 0.7849 -14.68% | BITO 10.4101 -0.48% | SOXS 18.0999 -2.85% | NVTS 15.575 17.99% | BURU 0.2301 15.05% | INTC 66.515 1.24% | PLUG 3.0999 -3.73% | NVDA 200.15 -0.95% | ONDS 10.9199 1.77% | OPEN 5.82 8.79% | POET 10.3 19.91% | SOWG 0.1595 -33.51% | TSLL 13.04 -1.88% | TQQQ 57.91 -0.29% | NOK 10.455 -1.37% | TOVX 0.3243 -20.90% | HIMS 29.805 -3.89% | SOXL 98.64 2.81% | SOUN 7.905 -4.99% | BMNG 1.5101 -2.57% | SLNH 1.5176 8.40% | CLIK 3.46 34.63% | SOFI 19.168 -1.70% | LCID 7.335 8.67% | SQQQ 57.08 0.30% | SPDN 9.175 0.38% | HYG 80.435 -0.18% | SNAP 5.725 -4.58% | SMR 11.995 -6.22% | AAL 11.88 -2.94% | TSLA 389 -0.89% | NVD 5.6984 1.94% | NFLX 93.2855 -1.63% | BULL 7.12 1.57% | PLTR 146.67 0.53% | BIYA 1.1902 36.79% | HTZ 7.04 -9.86% | BTG 4.94 0.00% | TDIC 0.9913 48.07% | BBAI 3.845 0.26%

Phreesia, Inc. (NYSE:PHR) Reports Strong Revenue Growth Despite EPS Miss

(NYSE:PHR) is a healthcare technology company that provides patient intake management solutions. It helps healthcare providers streamline their operations and improve patient experiences. The company competes with other healthcare technology firms like Cerner and Allscripts. On March 30, 2026, Phreesia reported earnings per share (EPS) of $0.02, which was below the estimated $0.06. However, the company generated revenue of approximately $127.1 million, slightly surpassing the estimated $126.8 million.

Despite the lower-than-expected EPS, Phreesia achieved several financial milestones for the fiscal year ending January 31, 2026. The company reported a positive GAAP net income of $2.3 million and exceeded $100 million in Adjusted EBITDA. Additionally, Phreesia generated $50 million in free cash flow, with net cash from operating activities reaching $78.8 million. These achievements reflect the company's strong financial performance and operational efficiency.

Phreesia's total revenue for the fiscal fourth quarter was $127.1 million, marking a 16% increase compared to the previous year. The average number of healthcare services clients (AHSCs) rose by 7% year-over-year to 4,658, while total revenue per AHSC increased by 8% to $27,279. This growth indicates the company's ability to expand its client base and increase revenue per client, contributing to its overall financial success.

Despite these positive developments, Phreesia's shares experienced a decline of 5.8%, closing at $10.98 on Friday. Mizuho analyst Steven Valiquette maintained an Outperform rating for Phreesia but adjusted the price target from $22 to $19 on March 24, 2026. The company's stock opened at $11.88 on Monday, showing a 0.9% increase. Phreesia's stock has experienced a 52-week low of $10.75 and a high of $32.76, reflecting its volatility in the market.

Phreesia's financial health is supported by a quick and current ratio of 2.44, with a debt-to-equity ratio of 0.01. The company's market capitalization stands at $716 million and a beta of 0.67. These metrics indicate that Phreesia has a strong liquidity position and low leverage, which can help it navigate market fluctuations and invest in future growth opportunities.

Published on: March 31, 2026